Intravenous immune globulins: An update for clinicians

Transfusion

Volumn 43, Issue 10, 2003, Pages 1460-1480

  Knezevic Maramica, Irina ^b   Kruskall, Margot S ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; GAMAIMUNE N; GAMMAGARD S/D; GAMMAR P I.V.; IDIOTYPIC ANTIBODY; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; IVEEGAM EN; PANGLOBULIN; POLYGAM S/D; BLOOD GROUP ANTIGEN; CYTOKINE;

ANAPHYLAXIS; ANTIBODY SCREENING; ASEPTIC MENINGITIS; B LYMPHOCYTE; CAPILLARY LEAK SYNDROME; CHILL; CLINICAL TRIAL; COMPLEMENT ACTIVATION; DISEASE TRANSMISSION; DRUG CONTAMINATION; DRUG INDICATION; DRUG INFUSION; DRUG MANUFACTURE; DRUG MECHANISM; DRUG USE; ECZEMA; FEVER; FLUSHING; HEADACHE; HEMOLYSIS; HEPATITIS C; HISTORY OF MEDICINE; HUMAN; HYPOGAMMAGLOBULINEMIA; HYPOTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNE DEFICIENCY; IMMUNOMODULATION; IMMUNOTHERAPY; INFECTION; INFECTION RISK; INJECTION PAIN; KIDNEY FAILURE; LICENSING; LUNG DISEASE; LUNG EDEMA; MUCOCUTANEOUS LYMPH NODE SYNDROME; PASSIVE IMMUNIZATION; PLASMAPHERESIS; PRION DISEASE; PROPHYLAXIS; REVIEW; SHOCK; SKIN MANIFESTATION; T LYMPHOCYTE; THROMBOEMBOLISM; TOXIC SHOCK SYNDROME; BONE MARROW TRANSPLANTATION; DRUG ANTAGONISM; IMMUNOLOGY; LYMPHOCYTE; METABOLISM; PHAGOCYTOSIS; PHYSIOLOGY;

AUTOANTIBODIES; BLOOD GROUP ANTIGENS; BONE MARROW TRANSPLANTATION; COMPLEMENT ACTIVATION; CYTOKINES; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; LYMPHOCYTES; PHAGOCYTOSIS;

EID: 0142103746     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00519.x     Document Type: Review

References (248)

1. Parti R, Mankarious S. Stability assessment of lyophilized intravenous immunoglobulin after reconstitution in glass containers and poly (vinyl chloride) bags. Biotechnol Appl Biochem 1997;25:13-8.
2. McKhann CF, Green AA, Coady H. Factors influencing the effectiveness of placental extract in the prevention and modification of measles. J Pediatr 1935;6:603-14.
3. Ordman CW, Gennings CG Jr, Janeway CA. Chemical, clinical, and immunological studies on the products of human plasma fractionation. XII. The use of concentrated normal human serum gamma globulin (human immune serum globulin) in the prevention and attenuation of measles. J Clin Invest 1944;23:541-9.
4. Stokes J Jr, Maris EP, Gellis SS. Chemical, clinical, and immunological studies on the products of human plasma fractionation. XI. The use of concentrated normal human serum gamma globulin (human immune serum globulin) in the prophlylaxis and treatment of measles. J Clin Invest 1944;23:540.
5. Stokes J Jr, Neefe JR. The prevention and attenuation of infectious hepatitis by gamma globulin. JAMA 1945;127:144-5.
6. Bruton OC. Agammaglobulinemia. Pediatrics 1952;52:722-8.
7. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991;325:110-7.
8. Cohn EJ, Strong LE, Hughes WL Jr., et al. Preparation and properties of serum and plasma proteins: IV. a system for the separation into fractions of the protein and lipoprotein components of biological tissues and fluids. J Am Chem Soc 1946;68:459-74.
9. Barandun S, Isliker H. Development of immunoglobulin preparations for intravenous use. Vox Sang 1986;51:157-60.
10. Blanchette V, Carcao M. Intravenous immunoglobulin G and anti-D as therapeutic interventions in immune thrombocytopenic purpura. Transfus Sci 1998;19:279-88.
11. Imbach P, d'Apuzzo V, Hirt A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet 1981;1:1228-31.
12. Kazatchkine MD, Kaveri SV. Immunomodulation of autoimmune and inflammatory diseases with intravenous immune globulin. N Engl J Med 2001;345:747-55.
13. Dietrich G, Algiman M, Sultan Y, et al. Origin of anti-idiotypic activity against anti-factor VIII autoantibodies in pools of normal human immunoglobulin G (IVIg). Blood 1992;79:2946-51.
14. Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol 2002;51:673-80.
15. Tankersley DL. Dimer formation in immunoglobulin preparations and speculations on the mechanism of action of intravenous immune globulin in autoimmune diseases. Immunol Rev 1994;139:159-72.
16. Spellberg B. Mechanism of intravenous immune globulin therapy. N Engl J Med 1999;341:57-8.
17. Ott VL, Fong DC, Cambier JC. Fcγ RIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol 2001;108:S95-8.
18. Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999;340:227-8.
19. Hansen RJ, Balthasar JP. Effects of intravenous immunoglobulin on platelet count and antiplatelet antibody disposition in a rat model of immune thrombocytopenia. Blood 2002;100:2087-93.
20. Bleeker WK, Teeling JL, Hack CE. Accelerated autoantibody clearance by intravenous immunoglobulin therapy. Studies in experimental models to determine the magnitude and time course of the effect. Blood 2001;98:3136-42.
21. Mollnes TE, Jogasen K, De Carolis C, et al. High-dose intravenous immunoglobulin treatment activates complement in vivo. Scand J Immunol 1998;48:312-7.
22. Mollnes TE, Andreassen IH, Hogasen K, et al. Effect of whole and fractionated intravenous immunoglobulin on complement in vitro. Mol Immunol 1997;34:719-29.
23. Aukrust P, Gullestad L, Lappegård KT, et al. Complement activation in patients with congestive heart failure: effect of high-dose intravenous immunoglobulin treatment. Circulation 2001;104:1494-500.
24. Basta M, Langlois PF, Marques M, et al. High-dose intravenous immunoglobulin modifies complement-mediated in vivo clearance. Blood 1989;74:326-33.
25. Basta M, Fries LF, Frank MM. High doses of intravenous Ig inhibit in vitro uptake of C4 fragments onto sensitized erythrocytes. Blood 1991;77:376-80.
26. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology 1998;51:S2-S8.
27. Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 2001;291:484-6.
28. Teeling JL, Jansen-Hendriks T, Kuijpers TW, et al. Therapeutic efficacy of intravenous immunoglobulin preparations depends on the immunoglobulin G dimers: studies in experimental immune thrombocytopenia. Blood 2001;98:1095-9.
29. Berchtold P, McMillan R. Intravenous immunoglobulin. New aspects of mechanism of action in chronic ITP. In: Imbach P, ed. Immunotherapy with intravenous immunoglobulins. London: Academic Press, 1991:245-52.
30. Aukrust P, Frøland SS, Liabakk NB, et al. Release of cytokines, soluble cytokine receptors, and interleukin-1 receptor antagonist after intravenous immunoglobulin administration in vivo. Blood 1994;84:2136-43.
31. Schlievert PM. Use of intravenous immunoglobulin in the treatment of staphylococcal and streptococcal toxic shock syndromes and related illnesses. J Allergy Clin Immunol 2001;108:S107-10.
32. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest 1993;91:602-7.
33. Vassilev T, Gelin C, Kaveri SV, et al. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol 1993;92:369-72.
34. Kaveri S, Vassilev T, Hurez V, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest 1996;97:865-9.
35. Kaveri S, Mouthon L, Kazatchkine MD. Immunomodulating effects of intravenous immunoglobulin in autoimmune and inflammatory diseases. J Neurol Neurosurg Psychiatry 1994;57:6-8.
36. Dalakas MC. Controlled studies with high-dose intravenous immunoglobulin in the treatment of dermatomyositis, inclusion body myositis, and polymyositis. Neurology 1998;51:S37-45.
37. Fazekas F, Deisenhammer F, Strasser-Fuchs S, et al. Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis: Lancet 1997;349:589-93.
38. Achiron A, Gabbay U, Gilad R, et al. Intravenous immunoglobulin treatment in multiple sclerosis: effect on relapses. Neurology 1998;50:398-402.
39. Bayry J, Lacroix-Desmazes S, Carbonneil C, et al. Inhibition of maturation and function of dendritic cells by intravenous immunoglobulin. Blood 2003;101:758-65.
40. Lam L, Whitsett CF, McNicholl JM, et al. Immunologically active proteins in intravenous immunoglobulin. Lancet 1993;342:678.
41. Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet 1993;341:789-90.
42. Warrington AE, Bieber AJ, Ciric B, et al. Immunoglobulin-mediated CNS repair. J Allergy Clin Immunol 2001;108: S121-5.
43. Kuhlmann T, Wendling U, Nolte C, et al. Differential regulation of myelin phagocytosis by macrophages/ microglia, involvement of target myelin, Fc receptors and activation by intravenous immunoglobulins. J Neuroscience Res 2002;67:185-90.
44. Vassilev TL, Kazatchkine MD, Van Huyen JP, et al. Inhibition of cell adhesion by antibodies to Arg-Gly-Asp (RGD) in normal immunoglobulin for therapeutic use (intravenous immunoglobulin, IVIg). Blood 1999;93:3624-31.
45. Prasad NK, Papoff G, Zeuner A, et al. Therapeutic preparations of normal polyspecific IgG (IVIg) induce apoptosis in human lymphocytes and monocytes: a novel mechanism of action of IVIg involving the Fas apoptotic pathway. J Immunol 1998;161:3781-90.
46. Viard I, Wehrli P, Bullani R, et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 1998;282: 490-3.
47. Shapiro S, Shoenfeld Y, Gilburd B, et al. Intravenous gamma globulin inhibits the production of matrix metalloproteinase-9 in macrophages. Cancer 2002;95: 2032-7.
48. Steele RW, Burks AW Jr, Williams LW. Intravenous immunoglobulin: new clinical applications. Ann Allergy 1988;60:89-94.
49. Availability of immune globulin intravenous for treatment of immune deficient patients-United States 1997-98. MMWR 1999;48:159-62.
50. Nydegger UE, Mohacsi PJ, Escher R, Morell A. Clinical use of intravenous immunoglobulins. Vox Sang 2000;78:191-5.
51. Boshkov LK, Kelton JG. Use of intravenous gammaglobulin as an immune replacement and an immune suppressant. Transf Med Rev 1989;3:82-120.
52. Bussel JB, Fitzgerald-Pedersen J, Feldman C. Alteration of two doses of intravenous gammaglobulin in the maintenance treatment of patients with immune thrombocytopenic purpura: more is not always better. Am J Hematol 1990;33:184-8.
53. Bussel JB, Kimberly RP, Inman RD, et al. Intravenous gammaglobulin treatment of chronic idiopathic thrombocytopenic purpura. Blood 1983;62:480-6.
54. Bussel JB, Pham LC. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: a review of the literature. Vox Sang 1987;52: 206-11.
55. Godeau B, Lesage S, Divine M, et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993;82:1415-21.
56. Portielje JE, Westendorp RG, Kluin-Nelemans HC, Brand A. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001;97:2549-54.
57. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002;346:995-1008.
58. Gamm H, Huber C, Chapel H, et al. Intravenous immune globulin in chronic lymphocytic leukemia. Clin Exp Immunol 1994;97:17-20.
59. Weeks JC, Tierney MR, Weinstein MC. Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 1991;325:81-6.
60. Lee ML, Gale RP, Yap PL. Use of intravenous immunoglobulin to prevent or treat infections in persons with immune deficiency. Annu Rev Med 1997;48:93-102.
61. Schaad UB. The role of IVIG in pediatric HIV infection. In: Imbach P, ed. Immunotherapy with intravenous immunoglobulins. London: Academic Press, 1991:201-9.
62. Yap PL. Does intravenous immune globulin have a role in HIV-infected patients? Clin Exp Immunol 1994;97(Suppl 1):59-67.
63. Pahwa S. Children with AIDS. Vox Sang 1986;51:33-8.
64. Brady MT. Treatment of human immunodeficiency virus infection and its associated complications in children. J Clin Pharmacol 1994;34:17-29.
65. Siadak MF, Kopecky K, Sullivan KM. Reduction in transplant-related complications in patients given intravenous immunoglobulin after allogeneic marrow transplantation. Clin Exp Immunol 1994;97:53-7.
66. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. Recommendations of CDC, the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation. MMWR 2002;49:1-125.
67. Burns JC, Capparelli EV, Brown JA, et al. Intravenous gamma-globulin treatment and retreatment in Kawasaki disease. US/Canada Kawasaki Syndrome Study Group. Pediatr Infect Dis J 1998;17:1144-8.
68. Fukunishi M, Kikkawa M, Hamana K, et al. Prediction of non-responsiveness to intravenous high-dose γ-globulin therapy in patients with Kawasaki disease at onset. J Pediatr 2000;137:172-6.
69. Wang CL, Wu YT, Lee CJ, et al. Decreased nitric oxide production after intravenous immunoglobulin treatment in patients with Kawasaki disease. J Pediatr 2002;141: 560-5.
70. NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of disease. JAMA 1990;264:3189-93.
71. Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA 1995;273:1865-70.
72. Burckhardt JJ, Gardi A, Oxelius V-A, et al. Immunoglobulin G subclass distribution in three human intravenous immunoglobulin preparations. Vox Sang 1989;57:10-4.
73. Herrera AM, Saunders NB, Baker JR. Immunoglobulin composition of three commercially available intravenous immunoglobulin preparations. J Allergy Clin Immunol 1989;84:556-61.
74. Heiner DC. IgG subclass composition of intravenous immunoglobulin preparations: clinical relevance. Rev Infect Dis 1986;8(Suppl 4):S391-5.
75. 1 lipoprotein into subfractions of human plasma. J Am Chem Soc 1949;71:541-50.
76. Friedli H, Morgenthaler JJ. Kistler/Nitschmann plasma fractionation methods. Lancet 1985;1:1215.
77. Kistler P, Nitschmann H. Large scale production of human plasma fractions: eight years experience with the alcohol fractionation procedure of Nitschmann, Kistler, and Lergier. Vox Sang 1962;7:414-24.
78. Skvaril F, Gardi A. Differences among available immunoglobulin preparations for intravenous use. Pediatr Infect Dis J 1988;7:S43-S48.
79. Rieben R, Roos A, Muizert Y, et al. Immunoglobulin M-enriched human intravenous immunoglobulin prevents complement activation in vitro and in vivo in a rat model of acute inflammation. Blood 1999;93:942-51.
80. Hurez V, Kazatchkine MD, Vassilev T, et al. Pooled normal human polyspecific IgM contains neutralizing antiidiotypes to IgG autoantibodies of autoimmune patients and protects from experimental autoimmune disease. Blood 1997;90:4004-13.
81. Rütter GH. Requirements for safety and quality of intravenous immunoglobulin G preparations. J Neurol Neurosurg Psychiatry 1994;57(Suppl):2-5.
82. Bleeker WK, Teeling JL, Verhoeven AJ, et al. Vasoactive side effects of intravenous immunoglobulin preparations in a rat model and their treatment with recombinant platelet-activating factor acetylhydrolase. Blood 2000;95:1856-61.
83. Appropriate uses of human immunoglobulin in clinical practice. Memorandum from an IUIS/WHO meeting. Bull WHO 1982;60:43-7.
84. Barandun S, Kistler P, Jeunet F, Isliker H. Intravenous administration of human γ-globulin. Vox Sang 1962;7:157-64.
85. Tankersley DL, Preston MS, Finlayson JS. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol 1988;25:41-8.
86. Farrugia A, Poulis P. Intravenous immunoglobulin: regulatory perspectives on use and supply. Transf Med 2001;11:63-74.
87. Alving BM, Tankersley DL, Mason BL, et al. Contact-activated factors. contaminants of immunoglobulin preparations with coagulant and vasoactive properties. J Lab Clin Med 1980;96:334-44.
88. Bagdasarian A, Tonetta S, Harel W, et al. IVIG adverse reactions: potential role of cytokines and vasoactive substances. Vox Sang 1998;74:74-82.
89. Epstein JS, Zoon KC. Letter to Healthcare Providers. Important Drug Warning: Immune Globulin Intravenous (Human). Washington (DC): Center for Biologics Evaluation and Research, Food and Drug Administration, 13 November 1998.
90. Tan E, Hajinazarian M, Bay W, et al. Acute renal failure resulting from intravenous immunoglobulin therapy: Arch Neurol 1993;50:137-9.
91. Cayco AV, Perazella MA, Hayslett JP. Renal insufficiency after intravenous immune globulin therapy: a report of two cases and an analysis of the literature. J Am Soc Nephrol 1997;8:1788-94.
92. Sati HI, Ahya R, Watson HG. Incidence and associations of acute renal failure complicating high-dose intravenous immunoglobulin therapy. Br J Haematol 2001;113:556-7.
93. Steinberger B, Coleman TA. Multiple complications of IVIG therapy in a patient with Guillain-Barre syndrome. Am J Hematol 2001;67:59.
94. Lawn N, Wijdicks EFM, Burritt MF. Intravenous immune globulin and pseudohyponatremia. N Engl J Med 1998; 339:632.
95. Sekul E, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med 1994;121:259-62.
96. Scribner CL. Aseptic meningitis and intravenous immunoglobulin therapy (editorial). Ann Intern Med 1994;121:305-6.
97. Harkness K, Howell SJ, Davies-Jones GA. Encephalopathy associated with intravenous immunoglobulin treatment for Guillain-Barre syndrome. J Neurol Neurosurg Psychiatry 1996;60:586.
98. Constantinescu CS, Chang AP, McCluskey LF. Recurrent migraine and intravenous immune globulin therapy. N Engl J Med 1993;329:583-4.
99. Duhem C, Ries F, Dicato M. Intravenous immune globulins and hypothermia. Am J Hematol 1996;51:172-3.
100. Haplea SS, Farrar JT, Gibson GA, et al. Thromboembolic events associated with intravenous immunoglobulin therapy. Neurology 1997;48:A54.
101. Frame WD, Crawford RJ. Thrombotic events after intravenous immunoglobulin. Lancet 1986;2:468.
102. Go RS, Call TG. Deep venous thrombosis of the arm after intravenous immunoglobulin infusion: case report and literature review of intravenous immunoglobulin-related thrombotic complications, Mayo Clin Proc 2000;75:83-5.
103. Elkayam O, Paran D, Milo R, et al. Acute myocardial infarction associated with high dose intravenous immunoglobulin infusion for autoimmune disorders: a study of four cases. Ann Rheum Dis 2000;59:77-80.
104. Fishman DN, Smilovitch M. Intravenous immunoglobulin, blood viscosity and myocardial infarction. Can J Cardiol 1997;13:775-6.
105. Rosenbaum JT. Myocardial infarction as a complication of immunoglobulin therapy. Arthritis Rheumatol 1997;40: 1732-3.
106. Paolini R, Fabris F, Cella G. Acute myocardial infarction during treatment with intravenous immunoglobulin for idiopathic thrombocytopenic purpura (ITP). Am J Hematol 2000;65:177-6.
107. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology 1994;44:223-6.
108. Alliot C, Rapin JP, Besson M, et al. Pulmonary embolism after intravenous immunoglobulin. J Royal Soc Med 2001;94:187-8.
109. Harkness KA, Goulding P. Central retinal vein occlusion complicating treatment with intravenous immunoglobulin. Eye 2000;14:662-3.
110. Oh KT, Boldt C, Danis RP. Iatrogenic central retinal vein occlusion and hyperviscosity associated with high-dose intravenous immunoglobulin administration. Am J Ophthalmol 1997;124:416-8.
111. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients. Lancet 1986;2:217-8.
112. Silbert PL, Knezevic WV, Bridge D. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology 1992;42:257-8.
113. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology 1994;44:1180-1.
114. Kwan T, Keith P. Stroke following intravenous immunoglobulin infusion in a 28-year-old male with common variable immune deficiency: a case report and literature review. Can J Allergy Clin Immunology 1999;4: 250-3.
115. Wolff SN, Fay JW, Herzig RH, et al. High-dose weekly intravenous immunoglobulin to prevent infections in patients undergoing autologous bone marrow transplantation or severe myelosuppressive therapy: a study of the American Bone Marrow Transplant Group. Ann Intern Med 1993;118:937-42.
116. Wolberg AS, Kon RH, Monroe DM, Hoffman M. Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations. Am J Hematol 2000;65:30-4.
117. Reinhart WH, Berchtold PE. Effect of high-dose intravenous immunoglobulin therapy on blood rheology. Lancet 1992;339:662-4.
118. Anonymous. FDA interim statement regarding immune globulin intravenous (IVIG). 8-27-.(GENERIC) Ref Type: Report. Washington, DC: FDA, 2002.
119. Cunningham-Rundles C, Zhou Z, Mankarious S, Courter S. Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies. J Clin Immunol 1993;13:272-8.
120. Sandler SG, Mallory D, Malamut D, Eckrich R. IgA anaphylactic transfusion reactions. Transf Med Rev 1995;9:1-8.
121. de Albuquerque Campos R, Sato MN, da Silva Duarte AJ. IgG anti-IgA subclasses in common variable immunodeficiency and association with severe adverse reactions to intravenous immunoglobulin therapy. J Clin Immunol 2000;20:77-82.
122. Nydegger UE, Sturzenegger M. Adverse effects of intravenous immunoglobulin therapy. Drug Safety 1999;21:171-85.
123. Rizk A, Gorson KC, Kenney L, Weinstein R. Transfusion-related acute lung injury after the infusion of IVIG. Transfusion 2001;41:262-8.
124. Duhem C, Dicato MA, Ries F. Side-effects of intravenous immune globulins. Clin Exp Immunol 1994;97:79-83.
125. Iannaccone S, Sferrazza B, Quattrini A, et al. Pompholyx (vesicular eczema) after IV immunoglobulin therapy for neurologic disease. Neurology 1999;53:1154-5.
126. Mitra G, Wong MF, Mozen MM, et al. Elimination of infectious retroviruses during preparation of immunoglobulins. Transfusion 1986;26:394-7.
127. Uemura Y, Yang YHJ, Heldebrant CM, et al. Inactivation and elimination of viruses during preparation of human intravenous immunoglobulin. Vox Sang 1994;67:246-54.
128. Hamamoto Y, Harada S, Yamamoto N, et al. Elimination of viruses (human immunodeficiency, hepatitis B, vesicular stomatitis and sindbis viruses) from an intravenous immunoglobulin preparation. Vox Sang 1987;53:65-9.
129. Wells MA, Wittek AE, Epstein JS, et al. Inactivation and partition of human T-cell lymphotrophic virus, type III, during ethanol fractionation of plasma. Transfusion 1986;26:210-3.
130. Yap PL. Intravenous immunoglobulin and hepatitis C virus: an overview of transmission episodes with emphasis on manufacturing data. Clin Therapeutics 1996;18(Suppl B): 43-58.
131. Chandra S, Cavanaugh JE, Lin CM, et al. Virus reduction in the preparation of intravenous immune globulin: in vitro experiments. Transfusion 1999;39:249-7.
132. Yei S, Yu MW, Tankersley DL. Partitioning of hepatitis C virus during Cohn-Oncley fractionation of plasma. Transfusion 1992;32:824-8.
133. Nakamura S, Sato T. Acute hepatitis B after administration of gammaglobulin. Lancet 1976;1:487.
134. Bresee JS, Mast EE, Coleman PJ, et al. Hepatitis C virus infection associated with administration of intravenous immune globulin: a cohort study. JAMA 1996;276: 1563-7.
135. Lever AML, Brown D, Webster ADB, Thomas HC. Non-A, non-B hepatitis occurring in agammaglobulinemic patients after intravenous immunoglobulin. Lancet 1984;2:1062-4.
136. Ochs HD, Fischer SH, Virant FS, et al. Non-A, non-B hepatitis after intravenous immunoglobulin. Lancet 1985;1:404-5.
137. Ochs HD, Fischer SH, Virant FS, et al. Non-A, non-B hepatitis after intravenous gammaglobulin. Lancet 1986;1:322-3.
138. Björkander J, Cunningham-Rundles C, Lundin P, et al. Intravenous immunoglobulin prophylaxis causing liver damage in 16 of 77 patients with hypogammaglobulinemia or IgG subclass deficiency. Am J Med 1988;84:107-11.
139. Bjoro K, Froland SS, Yun Z, et al. Hepatitis C infection in patients with primary hypogammaglobulinemia after treatment with contaminated immune globulin. N Engl J Med 1994;331:1607-11.
140. Taliani G, Guerra E, Rosso R, et al. Hepatitis C virus infection in hypogammaglobulinemic patients receiving long-term replacement with intravenous immunoglobulin. Transfusion 1995;35:103-7.
141. Williams PE, Yap PL, Gillon J, et al. Transmission of non-A, non-B hepatitis by pH 4-treated intravenous immunoglobulin. Vox Sang 1989;57:15-8.
142. Yu MY, Mason BL, Tankersley DL. Detection and characterization of hepatitis C virus RNA in immune globulins. Transfusion 1994;34:596-602.
143. Nübling CM, Gröner A, Löwer J. GB virus C/Hepatitis G virus and intravenous immunoglobulins. Vox Sang 1998;75: 189-92.
144. Rugolotto S, Padovani EM, Sanna A, et al. Intrauterine anemia due to parvovirus B19: successful treatment with intravenous immunoglobulins. Haematologica 1999;84:668-9.
145. Chuhjo T, Nakao S, Matsuda T. Successful treatment of persistent erythroid aplasia caused by parvovirus B 19 infection in a patient with common variable immunodeficiency with low-dose immunoglobulin. Am J Hematol 1999;60:222-4.
146. Koduri PR, Kumapley R, Valladeres J, Teter C. Chronic pure red cell aplasia caused by parvovirus B19 in AIDS: use of intravenous immunoglobulin-a report of eight patients. Am J Hematol 1999;61:16-20.
147. Sharma VR, Fleming DR, Slone SP. Pure red cell aplasia due to parvovirus B19 in a patient treated with rituximab. Blood 2000;96:1184-6.
148. Viguier M, Guillevin L, Laroche L. Treatment of parvovirus B19-associated polyarteritis nodosa with intravenous immune globulin. N Engl J Med 2001;344:1481-2.
149. Kurtzman G, Frickhofen N, Kimball J, et al. Pure red-cell aplasia of 10 years' duration due to persistent parvovirus B19 infection and its cure with immunoglobulin therapy. N Engl J Med 1989;321:519-23.
150. Young NS. Parvovirus infection and its treatment. Clin Exp Immunol 1996;104:26-30.
151. Prowse C, Ludlam CA, Yap PL. Human parvovirus B19 and blood products. Vox Sang 1997;72:1-10.
152. Hayakawa F, Imada K, Towatari M, Saito H. Life-threatening human parvovirus B19 infection transmitted by intravenous immune globulin. Br J Haematol 2002;118:1187-9.
153. Erdman DD, Anderson BC, Török TJ, et al. Possible transmission of parvovirus B19 from intravenous immune globulin. J Med Virol 1997;53:233-6.
154. Santagostino E, Mannucci PM, Gringeri A, et al. Transmission of parvovirus B19 by coagulation factor concentrates exposed to 100 degrees C heat after lyophilization. Transfusion 1997;37:517-22.
155. Schmidt I, Blümel J, Seitz H, et al. Parvovirus B19 DNA in plasma pools and plasma derivatives. Vox Sang 2001;81: 228-35.
156. Yap PL, Leaver HA, Gillon J. Prions: properties, cocurrence, modes of transmission and relevance for blood transfusion and blood derivatives. Vox Sang 1998;74(Suppl 2): 131-4.
157. Brown P, Cervenakova L, McShane LM, et al. Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt-Jakob disease in humans. Transfusion 1999; 39:1169-78.
158. Reichl HE, Foster PR, Welch AG, et al. Studies on the removal of a bovine spongiform encephalopathy-derived agent by processes used in the manufacture of human immunoglobulin. Vox Sang 2002;83:137-45.
159. Biswas RM, Nedjar S, Wilson LT, et al. The effect on the safety of intravenous immunoglobulin of testing plasma for antibody to hepatitis C. Transfusion 1994;34:100-4.
160. Lichtiger B, Rogge K. Spurious serologic test results in patients receiving infusions of intravenous immune gammaglobulin. Arch Pathol Lab Med 1991;115:467-9.
161. Mateos ML, Camerero C, Maldonado S, et al. Antibodies to hepatitis C virus in human immunoglobulins: clinical meaning and diagnostic difficulties in children undergoing bone marrow transplant. Bone Marrow Transplantation 1994;14:95-7.
162. Karna P, Murray DL, Valduss D, et al. Passive transfer of hepatitis antibodies during intravenous administration of immune globulin. J Pediatr 1994;125:463-5.
163. Antonelli A, Neri S, Gasperini L, et al. Liver function tests, hepatitis A, B, C markers and HIV antibodies in patients with Basedow's ophthalmopathy treated with intravenous immunoglobulins. Clin Ter 1992;141:55-61.
164. Thurmann PA, Sonnenburg C, Valentova K, et al. Pharmacokinetics of viral antibodies after administration of intravenous immunoglobulin in patients with chronic lymphocytic leukemia or multiple myeloma. Eur J Clin Pharmacol 2001;57:235-41.
165. Daily J, Werner B, Soiffer R, Fingeroth JIGIV. A potential role for hepatitis B prophylaxis in the bone marrow peritransplant period. Bone Marrow Transplantation 1998;21:739-42.
166. Rossi KQ, Nickel JR, Wissel ME, O'Shaughnessy RW. Passively acquired treponemal antibody from intravenous immunoglobulin therapy in a pregnant patient. Arch Pathol Lab Med 2002;126:1237-8.
167. Luyasu V, Mullier S, Bauraina O, Dupuis M. An unusual case of anti-Borrelia burgdorferi immunoglobulin G seroconversion caused by administration of intravenous gammaglobulins. Clin Microbiol Infect 2001;7:697-9.
168. Echevarria JM, Leon P, Domingo CJ, et al. Laboratory diagnosis and molecular epidemiology of an outbreak of hepatitis C virus infection among recipients of human intravenous immunoglobulin in Spain. Transfusion 1996;36:725-30.
169. Gordon JM, Cohen P, Finlayson JS. Levels of anti-A and anti-B in commercial immune globulins. Transfusion 1980;20:90-2.
170. Niosi P, Lundberg J, McCullough J, et al. Blood group antibodies in human immune serum globulin. N Engl J Med 1971;285:1435-6.
171. Buchs JP, Nydegger UE. Quantitation of anti-A and anti-B IgG antibodies in therapeutic i.v. immunoglobulin by indirect ELISA. Transfus Sci 1990;11:113-21.
172. Okubo S, Ishida T, Yasunaga K. Hemolysis after intravenous immune globulin therapy: relation to IgG subclasses of red cell antibody. Transfusion 1990;30:436-8.
173. Robertson VM, Dickson LG, Romond EH, Ash RC. Positive antiglobulin tests due to intravenous immunoglobulin in patients who received bone marrow transplant. Transfusion 1987;27:28-31.
174. Hoppe I. Antibody screening of commercially available immunoglobulins: erythrocyte-, HLA- and autoantibodies. Blut 1979;39:9-16.
175. Copelan EA, Strohm PL, Kennedy MS, Tutschka PJ. Hemolysis following intravenous immune globulin. Transfusion 1986;26:410-2.
176. Brox AG, Cournoyer D, Sternbach M, Spurll G. Hemolytic anemia following intravenous gamma globulin administration. Am J Med 1987;82:633-5.
177. Nicholls MD, Cummins JC, Davies VJ, Greenwood JK. Haemolysis induced by intravenously-administered immunoglobulin. Med J Australia 1989;150:404-6.
178. Kessary-Shoham H, Levy Y, Schoenfeld Y, et al. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimmunity 1999;13:129-35.
179. Sturgill MG, Nagabandi SR, Drachtman RA, et al. The effect of ABO and Rh blood type on the response to intravenous immune globulin (IVIG) in children with immune thrombocytopenic purpura (ITP). J Pediatric Hematol/Oncol 1997;19:523-5.
180. Lassiter HA, Bibb KW, Bertolone SJ, et al. Neonatal immune neutropenia following the administration of intravenous immune globulin. Am J Ped Hematol Oncol 1993;15:120-3.
181. Ben-Chetrit E, Putterman C. Transient neutropenia induced by intravenous immune globulin N Engl J Med 1992;326: 270-1.
182. Tam DA, Morton LD, Stroncek DF, Leshner RT. Neutropenia in a patient receiving intravenous immune globulin. J Neuroimmunol 1996;64:175-8.
183. Teeling JL, De Groot ER, Eerenberg AJ, et al. Human intravenous immunoglobulin (IGIV) preparations degranulate human neutrophils in vitro. Clin Exp Immunol 1998;114:264-70.
184. Teeling JL, Bleeker WK, Rigter GMM, et al. Intravenous immunoglobulin preparations induce mild activation of neutrophils in vivo via triggering of macrophages: studies in a rat model. Br J Haematol 2001;112:1031-40.
185. Scott JR. Immunotherapy for recurrent miscarriage. Cochrane Database Syst Rev 2003;1:CD000112.
186. Stricker RB, Steinleitner A, Bookoff CN, et al. Successful treatment of immunologic abortion with low-dose intravenous immunoglobulin. Fertil Steril 2000;73:536-40.
187. Branch DW, Peaceman AM, Druzin M, et al. A multi-center, placebo- controlled pilot study of intravenous immune globulin treatment of phospholipid syndrome during pregnancy. Am J Obstet Gynecol 2000;182:122-7.
188. Salmun LM, Barlan I, Wolf HM, et al. Effect of intavenous immunoglobulin on steroid consumption in patients with severe asthma: a double-blind, placebo-controlled, randomized trial. J Allergy Clin Immunol 1999;103:810-5.
189. Kishiyama JL, Valacer D, Cunningham-Rundles C, et al. A multicenter, randomized, double-blind, placebo-controlled trial of high-dose intravenous immunoglobulin for oral corticosteroid-dependent asthma. Clin Immunol 1999; 91:126-33.
190. Niggemann B, Leupold W, Schuster A, et al. Prospective, double-blind, placebo-controlled, multicentre study on the effect of high-dose, intravenous immunoglobulin in children and adolescents with severe bronchial asthma. Clin Exp Allergy 1998;28:205-10.
191. Hunsinger DM, Nguyen T, Zebraski SE, Raffa RB. Is there a basis for novel pharmacotherapy of autism? Life Sci 2000;67: 1667-82.
192. Hahn AF. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin. Neurology 1998;51:S16-21.
193. Hughes R, Bensa S, Willison H, et al. Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50: 195-201.
194. Mendell JR, Barohn RJ, Freimer ML, et al. Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 2001;56:445-9.
195. Cocito D, Ciaramitaro P, Isoardo G, et al. Intravenous immunoglobulin as first treatment in diabetics with concomitant distal symmetric axonal polyneuropathy and CIDP. J Neurol 2002;249:719-22.
196. Colagiuri S, Leong GM, Thayer Z, et al. Intravenous immunoglobulin therapy for autoimmune diabetes mellitus. Clin Exp Rheumatol 1996;14:S93-7.
197. Sharma KR, Cross J, Ayyar DR, et al. Diabetic demyelinating polyneuropathy responsive to intravenous immunoglobulin therapy. Arch Neurol 2002;59:751-7.
198. Sater RS, Rostami A. Treatment of Guillain-Barre syndrome with intravenous immunoglobulin. Neurology 1998;51: S9-15.
199. van der Meche FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. Dutch Guillain-Barre Study Group. N Engl J Med 1992;326:1123-9.
200. Kuwabara S, Mori M, Ogawara K, et al. Intravenous immunoglobulin therapy for Guillain-Barre syndrome with IgG anti-GM1 antibody. Muscle Nerve 2002;24:54-8.
201. Schwartz RS, Gabriel DA, Aledort LM, et al. A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood 1995;86:797-804.
202. Grunewald M, Beneke H, Guthner C, et al. Acquired haemophilia: experiences with a standardized approach. Haemophilia 2001;7:164-9.
203. Viallard JF, Pellegrin JL, Vergnes C, et al. Three cases of acquired von Willebrand disease associated with systemic lupus erythematosus. Br J Haematol 1999;105:532-7.
204. Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM. Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 1998;92:2707-11.
205. Anes PR, Nardiello S, Tommasino C. Efficacy of low dose intravenous immunoglobulins for post-splenectomy of autoimmune haemolytic anaemia in a patient with hereditary spherocytosis. Clin Lab Haematol 2000;22:225-8.
206. Hartert A, Willenbacher W, Gunzelmann S, et al. Successful treatment of thrombocytopenia and hemolytic anemia with IVIG in a patient with lupus-like syndrome after mismatched related PBSCT. Bone Marrow Transplantation 2001;27:337-40.
207. Bux J, Behrens G, Jaeger G, Welte K. Diagnosis and clinical course of autoimmune neutropenia in infancy: analysis of 240 cases. Blood 1998;91:181-6.
208. Jolly MC, Letsky EA, Fisk NM. The management of fetal alloimmune thrombocytopenia. Prenatal Diagnosis 2002;22:96-8.
209. Silver RM, Porter TF, Branch DW, Esplin MS, Scott JR. Neonatal alloimmune thrombocytopenia: antenatal management. Am J Obstet Gynecol 2000;182:1233-8.
210. Gaddipati S, Berkowitz RL, Lembet AA, et al. Initial fetal platelet counts predict the response to intravenous gammaglobulin therapy in fetuses that are affected by PLA1 compatibility. Am J Obstet Gynecol 2001;185:976-80.
211. Semple JW, Kim M, Lazarus AH, Freedman J. γ-globulins prepared from sera of multiparous women bind anti-HLA antibodies and inhibit an established in vivo human alloimmune response. Blood 2002;100:1055-9.
212. Ohlsson A, Lacy JB. Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev 2001;2:CD001239.
213. Sandberg K, Fasth A, Berger A, et al. Preterm infants with low immunoglobulin G levels have increased risk of neonatal sepsis but do not benefit from prophylactic immunoglobulin G. J Pediatr 2000;137:623-8.
214. Körber J, Köttgen E, Renz H. A case of Crohn's disease with increased CD8 T-cell activation and remission during therapy with intravenous immunoglobulins. Scand J Gastroenterol 1998;33:1113-7.
215. Shintani N, Nakajima T, Nakakubo H, et al. Intravenous immunoglobulin (IVIG) treatment of experimental colitis induced by dextran sulfate sodium in rats. Clin Exp Immunol 1997;108:340-5.
216. Pyne D, Ehrenstein M, Morris V. The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases. Rheumatology 2002;41:367-74.
217. Asura E, Bick A, Brunner NG, et al. High-dose intravenous immunoglobulin in the management of myasthenia gravis. Arch Intern Med 1986;146:1365-8.
218. Howard JF Jr. Intravenous immunoglobulin for the treatment of acquired myasthenia gravis. Neurology 1998;51:S30-6.
219. Wolfe GI, Barohn RJ, Foster BM, et al. Randomized, controlled trial of intravenous immunoglobulin in myasthenia gravis. Muscle Nerve 2002;26:549-52.
220. Qureshi AI, Choudhry MA, Akbar MS, et al. Plasma exchange versus intravenous immunoglobulin treatment in myasthenic crisis. Neurology 1999;52:629-32.
221. Lisak RP. Intravenous immunoglobulins in multiple sclerosis. Neurology 1998;51:S25-9.
222. Sorensen PS, Fazekas F, Lee M. Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. European J Neurol 2002;9:557-63.
223. Federico P, Zochodne DW, Hahn AF, et al. Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 2000;55:1256-62.
224. Mueller-Eckhardt C, Kiefel V. High-dose IgG for post-transfusion purpura-revisited. Blut 1995;57:163-7.
225. Ziman A, Klapper E, Pepkowitz S, et al. A second case of post-transfusion purpura caused by HPA-5a antibodies: successful treatment with intravenous immunoglobulin. Vox Sang 2002;83:165-6.
226. Kaul R, McGeer A, Norrby-Teglund A, et al. Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome: a comparative observational study. Clin Infectious Dis 1999;28:800-7.
227. Alejandria MM, Lansang MA, Dans LF, Mantaring JB. Intravenous immunoglobulin for treating sepsis and septic shock (Cochrane Review). Cochrane Database Syst Rev 2001;2:CD001090.
228. Douzinas EE, Pitaridis MT, Louis G, et al. Prevention of infection in multiple trauma patients by high-dose intravenous immunoglobulins. Crit Care Med 2000;28:8-15.
229. Modi N, Carr R. Promising stratagems for reducing the burden of neonatal sepsis. Arch Dis Child Fetal Neonatal 2000;83:F150-3.
230. Dalakas MC, Fujii M, Li M, et al. High-dose intravenous immune globulin for stiff-person syndrome. N Engl J Med 2001;345:1870-6.
231. Hundt M, Manger K, Dorner T, et al. Treatment of acute exacerbation of systemic lupus erythematosus with high-dose intravenous immunoglobulin. Rheumatology 2000;39:1301-2.
232. Boletis JN, Ioannidis JPA, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999;354:569-70.
233. Paquet P, Jacob E, Damas P, Pierard GE. Treatment of drug-induced toxic epidermal necrolysis (Lyell's syndrome) with intravenous human immunoglobulins. Burns 2001;27: 652-5.
234. Magina S, Lisboa C, Gonsalves E, et al. A case of toxic epidermal necrolysis treated with intravenous immunoglobulin. Br J Dermatol 2002;142:191-2.
235. Scheuerman O, Nofech-Moses Y, Rachmel A, Ashkenazi S. Successful treatment of antiepileptic drug hypersensitivity syndrome with intravenous immune globulin. Pediatrics 2001;107:e14.
236. King SM. Immune globulin versus antivirals versus combination for prevention of cytomegalovirus disease in transplant recipients. Antiviral Res 1999;40:114-37.
237. Sechet A, Bridoux F, Bauwens M, et al. Prevention of cytomegalovirus infection and disease in high-risk renal transplant recipients with polyvalent intravenous immunoglobulins. Transplant Proc 2002;34:812-3.
238. Cote I, Deschesnes L, de Cotret PR, et al. New immunosuppressive regimens and cytomegalovirus infection after kidney transplantation: a retrospective study. Transplant Proc 2001;33:3626-9.
239. Montgomery RA, Zachary AA, Racusen LC, et al. Plasmapheresis and intravenous globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000;70:887-95.
240. Luke PP, Scantlebury VP, Jordan ML, et al. IVIG rescue therapy in renal transplantation. Transplant Proc 2001;33:1093-4.
241. Glotz D, Haymann JP, Sansonetti N, et al. Suppression of HLA-specific alloantibodies by high-dose intravenous immunoglobulins (IVIg): a potential tool for transplantation of immunized patients. Transplantation 1993;56:335-7.
242. Peraldi MN, Akposso K, Haumann JP, et al. Long-term benefit of intravenous immunoglobulins in cadaveric kidney retransplantation. Transplantation 1996;62:1670-3.
243. Wassmuth R, Hauser IA, Schuler K, et al. Differential inhibitory effects of intravenous immunoglobulin preparations on HLA-alloantibodies in vitro. Transplantation 2001;71:1436-42.
244. Jordan SC, Quartel AW, Czer LS, et al. Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action. Transplantation 1998;66:800-5.
245. Buhler L, Pidwell D, Dowling RD, et al. Different responses of human anti-HLA and anti-α-gal antibody to long-term intravenous immunoglobulin therapy. Xenotransplantation 1999;6:181-6.
246. Glotz D, Antoine C, Julia P, et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulins (IVIg). Am J Transplantation 2002;2:758-60.
247. Corales R, Chua J, Mawhorter S, et al. Significant posttransplant hypogammaglobulinemia in six heart transplant recipients: an emerging clinical phenomenon? Transplant Infectious Dis 2000;2:133-9.
248. Siegel J. Intravenous immune globulins. Pharmacy Prac News 2001:11-3.